

	Medication	Date Added	Date Removed	Additional Notes
Ceftriaxone ER drug-inf suspension		9/20/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Cefixime oral tablet		9/20/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Indacaterol		9/20/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Chondroline 15mg		9/20/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Roxadine		9/20/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Beyazet		9/20/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Enalapril		9/20/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Vincristine		11/15/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Tamiflu		11/15/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Wentvair		11/15/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Imiprida		11/15/2024	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Pymapad		11/17/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Astaxanthin Zumo		11/17/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Alavert		11/17/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Kemistry		6/1/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Symposio		6/1/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Zimberina		6/1/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
PA Naloxonum		4/16/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Melaminah-AEIN		4/29/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Colagene		6/4/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Stabiodis		6/4/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
PA Vidura		6/16/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Bunyntra		6/30/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Conceivance		7/2/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Genomelone		7/2/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Eurafit WVR		7/21/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
PA Purodus		8/5/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Anesthetix		11/1/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Ready		11/1/2025	N/A	PA Required See website - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/014786Orig1s01.pdf
Central All strengths		10/20/21	N/A	Class 2, at least 2 previously failed Patentes required
Muzigita		5/18/2021	N/A	Class 2, at least 2 previously failed Patentes required
Lactan Oment		9/6/2021	N/A	Class 2, at least 2 previously failed Patentes required
11/2/2021		11/2/2021	N/A	Class 2, at least 2 previously failed Patentes required
Lactan		11/2/2021	N/A	Class 2, at least 2 previously failed Patentes required
PA Gendia Epicon		12/24/2021	N/A	Class 2, at least 2 previously failed Patentes required
Jasufit (long-term)		12/24/2021	N/A	Class 2, at least 2 previously failed Patentes required
Argo Hydrogel and Dermal Spray		12/28/2021	N/A	Class 2, at least 2 previously failed Patentes required
Arrest		12/29/2021	N/A	Class 2, at least 2 previously failed Patentes required
Resolv		12/29/2021	N/A	Class 2, at least 2 previously failed Patentes required
Netix 24 mg/ml		1/14/2023	N/A	Class 2, at least 2 previously failed Patentes required
Carvedilol H 150mg Capsules		3/26/2023	N/A	Class 2, at least 2 previously failed Patentes required
Oxytetracycline		7/26/2023	N/A	Class 2, at least 2 previously failed Patentes required
Formosol Spray		7/26/2023	N/A	Class 2, at least 2 previously failed Patentes required
Nuclease CFC Cream		8/17/2023	N/A	Class 2, at least 2 previously failed Patentes required
Staphenocaps 200mg/cap, 300mg/mL		10/2/2023	N/A	Class 2, at least 2 previously failed Patentes required
Dovec DR Incubator Box		10/24/2023	N/A	Class 2, at least 2 previously failed Patentes required
Limmon 0.9% Qm Gel		1/16/2023	N/A	Class 2, at least 2 previously failed Patentes required
Softlase XR 20mg/mL, 30mg		2/29/2023	N/A	Class 2, at least 2 previously failed Patentes required
Set Infusion-Subit 0.4-0.5% (Sodium)		5/22/2023	N/A	Class 2, at least 2 previously failed Patentes required
Epigenate all strengths		6/26/2023	N/A	Class 2, at least 2 previously failed Patentes required
Formosol solution		7/2/2023	N/A	Class 2, at least 2 previously failed Patentes required
Foscoart capsule 60-300-40		8/21/2023	N/A	Class 2, at least 2 previously failed Patentes required
Epigenate all strengths		8/21/2023	N/A	Class 2, at least 2 previously failed Patentes required
Acidex 7 mg/ml		8/21/2023	N/A	Class 2, at least 2 previously failed Patentes required
Amesol XL all strengths		8/21/2023	N/A	Class 2, at least 2 previously failed Patentes required
9/13/2023		9/13/2023	N/A	Class 2, at least 2 previously failed Patentes required
Gallia 300mg & 450mg		13/4/2023	N/A	Class 2, at least 2 previously failed Patentes required
Phidin		3/14/2024	N/A	Class 2, at least 2 previously failed Patentes required
Alkamon phifer		3/14/2024	N/A	Class 2, at least 2 previously failed Patentes required
Lufanah XL		3/14/2024	N/A	Class 2, at least 2 previously failed Patentes required
Phyphix ER (all strengths)		3/14/2024	N/A	Class 2, at least 2 previously failed Patentes required
Chelera 300		4/1/2024	N/A	Class 2, at least 2 previously failed Patentes required
Harlow capsule		4/1/2024	N/A	Class 2, at least 2 previously failed Patentes required
10/17/2024		10/17/2024	N/A	Class 2, at least 2 previously failed Patentes required
Fluagenamine decanoate 100% lipids		10/17/2024	N/A	Class 2, at least 2 previously failed Patentes required
Vena patch		10/17/2024	N/A	Class 2, at least 2 previously failed Patentes required
Arvalol		10/17/2024	N/A	Class 2, at least 2 previously failed Patentes required
Ravuso		10/17/2024	N/A	Class 2, at least 2 previously failed Patentes required
Resolv suspension		10/17/2024	N/A	Class 2, at least 2 previously failed Patentes required
Carvedilol solution		2/6/2025	N/A	Class 2, at least 2 previously failed Patentes required
Bayat (all strengths)		2/6/2025	N/A	Class 2, at least 2 previously failed Patentes required
Amelma solution		7/11/2025	N/A	Class 2, at least 2 previously failed Patentes required
Phoar Respicard		7/11/2025	N/A	Class 2, at least 2 previously failed Patentes required
Navesol gel		7/11/2025	N/A	Class 2, at least 2 previously failed Patentes required
Phonar Patch (37.5, 62.5, 87.5 mg/ml)		7/11/2025	N/A	Class 2, at least 2 previously failed Patentes required
Clavido		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine vyme		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 2 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 5 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 10 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 15 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 20 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 25 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 30 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 35 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 40 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 45 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 50 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 55 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 60 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 65 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 70 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 75 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 80 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 85 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 90 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 95 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 100 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 105 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 110 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 115 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 120 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 125 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 130 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 135 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 140 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 145 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 150 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 155 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 160 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 165 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 170 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 175 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 180 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 185 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 190 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 195 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 200 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 205 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 210 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 215 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 220 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 225 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 230 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 235 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 240 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 245 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 250 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 255 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 260 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 265 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 270 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 275 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 280 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 285 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 290 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 295 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 300 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 305 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 310 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 315 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 320 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 325 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 330 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 335 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 340 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 345 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 350 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 355 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 360 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 365 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 370 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 375 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 380 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 385 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 390 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 395 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 400 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 405 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 410 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 415 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 420 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 425 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 430 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 435 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 440 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 445 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 450 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 455 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 460 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 465 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 470 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 475 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 480 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 485 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 490 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 495 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required
Ortine 500 mg/ml		11/4/2025	N/A	Class 2, at least 2 previously failed Patentes required

Medication	Date Added	Date Removed	Additional Notes
Fals	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Tobacromil 50mg/4ml	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Cheva	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Mefenamic 70mg	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Ergonomics 60mg capsule	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Mefenamic 125mg	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Ativone	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Aminid	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Omevoh	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Acron	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Kewell DR	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Gilia	4/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Sensilla	4/11/2025	N/A	Class 1 - at least 1 previously failed therapy required
Vagant Hydrate	4/11/2025	N/A	Class 1 - at least 1 previously failed therapy required
Labbort	5/6/2025	N/A	Class 1 - at least 1 previously failed therapy required
Smash	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Picocaine 1.25%	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Afrot	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Brownbone	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Stigimyl/mefenomic	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Sibogel	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Vafagra	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Rhodral	5/9/2025	N/A	Class 1 - at least 1 previously failed therapy required
Aluvom	6/2/2025	N/A	Class 1 - at least 1 previously failed therapy required
Avonox	6/17/2025	N/A	Class 1 - at least 1 previously failed therapy required
Adventum	6/17/2025	Moved to MAR PA 11/1/2025	Class 1 - at least 1 previously failed therapy required
Lypta	6/17/2025	Moved to MAR PA 11/1/2025	Class 1 - at least 1 previously failed therapy required
Hemay	7/7/2025	Moved to MAR PA 11/1/2025	Class 1 - at least 1 previously failed therapy required
Dichloral 40mg	7/8/2025	N/A	Class 1 - at least 1 previously failed therapy required
Anaprove 2% cream	7/25/2025	N/A	Class 1 - at least 1 previously failed therapy required
Sertral	7/25/2025	N/A	Class 1 - at least 1 previously failed therapy required
Enalapril powder	7/25/2025	N/A	Class 1 - at least 1 previously failed therapy required
Vita	8/4/2025	N/A	Class 1 - at least 1 previously failed therapy required
Asili Vials	8/15/2025	N/A	Class 1 - at least 1 previously failed therapy required
Metastar	8/27/2025	N/A	Class 1 - at least 1 previously failed therapy required
Acetaminophen/Phenobarbital/Alprazolam	11/9/2025	N/A	Data Not Covered (T AAC 105 10)
Acetaminophen/Phenobarbital	7/7/2026	N/A	Data Not Covered (T AAC 105 10)
Acetaminophen/Alprazolam	7/7/2026	N/A	Data Not Covered (T AAC 105 10)
Acetaminophen/Phenobarbital	8/1/2026	N/A	Data Not Covered (T AAC 105 10)
Ames XR	39/26/2026	N/A	Drug Not Covered (T AAC 105 10) or T AAC 105 10)
Acetaminophen Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Acetic Acid/Sodium Phosphate Powder	12/2/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Codexin Phosphate Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Entantra Base Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Entantra Capsule Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Hydrocodone Bitartrate Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Hydrocodone Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Methadone Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Minipress Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Nicotinic Nicotine Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Nitroglycerin Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Oxydrolone Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Salicylic Acid/Crate Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Sulfentran Powder	2/3/2021	N/A	Active Pharmaceutical Ingredient (API) not covered
Aurigen OTC (ISM AHCSS 4113 6439)	3/17/2021	N/A	Drug Not Covered - ISM or ISM not yet covered
Methylphenidate/Dextroamphetamine (D-AMP)	3/22/2021	N/A	Drug Not Covered - D-AMP or D-AMP not yet covered
Barbiturates Phenobarbital (ISN 4777)	3/22/2021	N/A	Drug Not Covered - D-AMP or D-AMP not yet covered
Naturox Oral Tablets	N/A	5/9/2021	PA requirement remained prior to implementation Renowned from Physio Authorization
Nutrin ER	9/28/2021	7/9/2021 - See New ERP Edit	Historical / Class 2 - at least 2 previously failed therapies required
Nutrin	9/28/2021	9/28/2021	Class 1 - at least 1 previously failed therapy required
Gabitol	2/9/2021	9/28/2021	Historical / Class 1 - at least 1 previously failed therapy required
Artemin™ SR	10/17/2021	10/17/2021	Historical / Class 2 - at least 2 previously failed therapies required
Trifluor	2/9/2021	7/9/2021	Historical / Class 1 - at least 1 previously failed therapy required
Nufarm	2/9/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Naxosin	4/19/2025	9/28/2021	Historical / Class 1 - at least 1 previously failed therapy required
Infecton Injection	2/9/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Parotia	2/9/2021	12/2/2021	Historical / Class 2 - at least 2 previously failed therapies required
Neas Relief PMV	9/28/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Natasta DNA combo pack	2/9/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Necura Chitosan Tablet	9/28/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Nedraquin DT Tablet	9/28/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Alvera Chron (all strengths)	9/28/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Transdermal Formons	3/23/2021	9/28/2021	Historical / Class 2 - at least 2 previously failed therapies required
Edural (all strengths)	3/23/2021	12/2/2021	Historical / Class 1 - at least 1

Medication	Date Added	Date Removed	Additional Notes
Colcefen M	9/16/2020	3/3/2022	Historical / Class 2 - at least 2 previously failed therapies required
Cosentyx ER	12/14/2018	3/3/2022	Historical / Class 2 - at least 2 previously failed therapies required
Flax	9/18/2020	3/3/2022	Historical / Class 2 - at least 2 previously failed therapies required
Felix-Poststar	9/19/2024	6/3/2022	Removed from Prior Authorization
Celebrex all strengths	9/8/2013	11/18/2022	Removed from Prior Authorization
Lenora	11/19/2021	3/3/2024	Class 1 - at least 1 previously failed therapy required
Everolimus	11/19/2021	3/3/2024	Class 1 - at least 1 previously failed therapy required
Domagat all strengths	3/20/2013	3/3/2024	Class 2 - at least 2 previously failed therapies required
Edron	9/28/2011	3/3/2024	Class 1 - at least 1 previously failed therapy required
Edronge 40mg	10/24/2012	3/3/2024	Class 1 - at least 1 previously failed therapy required
Everolimus capsule	7/25/2014	3/3/2024	Class 1 - at least 1 previously failed therapy required
Fluticasone	11/19/2021	3/3/2024	Class 1 - at least 1 previously failed therapy required
Fluticasone	11/19/2021	3/3/2024	Class 1 - at least 1 previously failed therapy required
Revant	9/17/2021	3/3/2024	Class 1 - at least 1 previously failed therapy required
Revant	11/1/2023	11/1/2024	Class 1 - at least 1 previously failed therapy required
Abilify Airmid	11/1/2023	11/1/2024	Class 2 - at least 2 previously failed therapies required
Revant	4/28/2016	10/1/2020	Historical / Class 2 - at least 2 previously failed therapies required
Revant	11/1/2023	10/1/2025	Historical / Class 2 - at least 2 previously failed therapies required